{"word_count": 487, "character_count": 4769}
Conference presentation.Over the recent decades, the influence of corporate interests &#8211; most notably from the cigarette, chemical, pharmaceutical, and food industries &#8211; on public health has attracted growing concerns and public attention. Within this context, one notion, that of &#8216;conflict of interest&#8217; (CoI), has become widespread and used as the main lens through which this influence and its problematic consequences on the construction of scientific knowledge, on the decisions taken by public authorities, and on heath practices is approached. The MEDICI research project has, over the last three years, explored how conflict of interest has been understood and used in the field of medicine with what kinds of responses. It has also aimed at understanding the effects of this problematization on the ways in which the various actors involved in the sector perform an organize their activities. This final conference will gather presentations laying out the main results of the MEDICI project as well as invited talks from leading scholars studying corporate influence on science and regulation.Organizing CommitteeBoris Hauray&#160;(Inserm),&#160;Henri Boullier&#160;(Inserm),&#160;Jean-Paul Gaudilli&#232;re&#160;(Inserm, EHESS) &#38;&#160;H&#233;l&#232;ne Michel&#160;(Universit&#233; de Strasbourg).ProgrammeDAY 1 &#8211; 9 December201913h30-14h &#8211; Introduction by&#160;Boris Hauray&#160;(Inserm), scientific coordinator of the MEDICI project14h-15h &#8211;&#160;Sergio Sismondo&#160;(Queen&#8217;s University) &#8220;Big Pharma&#8217;s Invisible Hands&#8221;15h15-17h15 -&#160;Panel #1 &#8211; Corporate Influence on the Production of Scientific KnowledgeChair:&#160;Catherine Bourgain&#160;(Inserm)Jill Fisher&#160;(UNC-Chapel Hill) &#8220;Investigating the Inherent Conflicts of Interest in Commercial Phase I Trials&#8221;.David Demortain&#160;(INRA) &#8220;The Pharmaceutical Industry and the Production of Regulatory Knowledge. Exploring the Systemic Determinants of Conflicts of Interests&#8221;.Melanie Jeske&#160;(UCSF) Conflict of Interest&#8217; or Simply &#8216;Interest&#8217;? Shifting Values in Translational Medicine.Boris Hauray&#160;(Inserm) &#8220;Publishing Impure Science. The Politics of Conflict of Interest in Medical Journals&#8221;.DAY 2 &#8211; 10 December 20199h15-10h15 &#8211;&#160;Marc Rodwin&#160;(Suffolk University) &#8220;Conflicts of Interest in Medicine-Causes and Cures&#8221;10h30-12h30 &#8211;&#160;Panel #2 &#8211; Regulatory Expertise and AgenciesChair:&#160;Daniel Benamouzig&#160;(CNRS)Nathalie Jas&#160;(INRA) &#8220;Industry Quiet Power. Shaping WHO/FAO Food Additives and Contaminants Expert Committees' Work in the Post-WWII period&#8221;.Annie Martin&#160;(CNRS) &#8220;Conflict of Interest and European Law. The European Medicines Agency's case&#8221;.J&#233;r&#244;me Greffion&#160;(Universit&#233; Paris 10) &#38;&#160;H&#233;l&#232;ne Michel&#160;(Universit&#233; de Strasbourg) &#8220;Medical Experts at work in a Committee of the French National Authority for Health&#8221;.14h-17h &#8211;&#160;Panel #3 &#8211; Physicians and Medical PracticesChair:&#160;Maurice Cassier&#160;(CNRS)Volker Hess&#160;(Charit&#233;) &#8220;Clinical research and the Nylon Curtain. The case of the GDR, 1960-1990&#8221;.Jean-Paul Gaudilli&#232;re&#160;(Inserm/EHESS) &#8220;Scientific Marketing and Conflict of Interest. Lessons from the Hormone Replacement Therapies Crisis&#8221;.Etienne Nouguez&#160;(CNRS) &#8220;Fighting over Generic Medicines. Struggles between Pharmaceutical Companies to Influence the Prescriptions of French Doctors and Pharmacists&#8221;.Henri Boullier&#160;(Inserm) &#38;&#160;J&#233;r&#244;me Greffion&#160;(Universit&#233; Paris 10) &#8220;The Materiality of Transparency. Constructing a Database on Physicians Funding&#8221;.DAY 3 &#8211; 11 december 201999h15-10h15 &#8211;&#160;Lisa Cosgrove&#160;(University of Massachusetts Boston) &#8220;Institutional Corruption in Psychiatry and Solutions for Reform&#8221;10h30-12h &#8211;&#160;Panel #4 &#8211; Critiques, mobilizations and affairsChair:&#160;Sezin Top&#231;u&#160;(CNRS)Christian Bonah&#160;&#38;&#160;Sol&#232;ne Lellinger&#160;(Universit&#233; de Strasbourg) &#8220;&#8216;This Corporation has &#8216;Anaesthetized&#8217; the Actors in the Drug Chain&#8217;. Influence Peddling and the Normality of Conflict of Interest in the Benfluorex Case&#8221;.Giovanni Prete&#160;(Universit&#233; Paris 13),&#160;Fran&#231;ois Dedieu&#160;(INRA) &#38; Jean-No&#235;l Jouzel&#160;(CNRS) &#8220;Denouncing Pesticides in France: Conflict of Interest as a Protest Repertoire&#8221;.S&#233;bastien Dalgalarrondo&#160;(CNRS) &#8220;Patient Mobilizations and Industry Influence: from AIDS to Alzheimer&#8221;.Conclusion.